PK of Filgotinib in Hepatic Impairment

Phase 1, open-label trial of filgotinib in rheumatoid arthritis (RA) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at 120 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 120 hours and 1 more. Started Apr 2018; status: completed.